156 related articles for article (PubMed ID: 38718434)
1. Computational insights into allosteric inhibition of focal adhesion kinase: A combined pharmacophore modeling and molecular dynamics approach.
Kumar V; Singh P; Parate S; Singh R; Ro HS; Song KS; Lee KW; Park YM
J Mol Graph Model; 2024 Jul; 130():108789. PubMed ID: 38718434
[TBL] [Abstract][Full Text] [Related]
2. Investigations of FAK inhibitors: a combination of 3D-QSAR, docking, and molecular dynamics simulations studies.
Cheng P; Li J; Wang J; Zhang X; Zhai H
J Biomol Struct Dyn; 2018 May; 36(6):1529-1549. PubMed ID: 28490269
[TBL] [Abstract][Full Text] [Related]
3. Design and screening of FAK, CDK 4/6 dual inhibitors by pharmacophore model, molecular docking, and molecular dynamics simulation.
Sun C; Feng L; Sun X; Yu R; Kang C
J Biomol Struct Dyn; 2021 Sep; 39(15):5358-5367. PubMed ID: 32627678
[TBL] [Abstract][Full Text] [Related]
4. CHK1 kinase inhibition: identification of allosteric hits using MD simulations, pharmacophore modeling, docking and MM-PBSA calculations.
Al-Shar'i N; Musleh SS
Mol Divers; 2022 Apr; 26(2):903-921. PubMed ID: 33686514
[TBL] [Abstract][Full Text] [Related]
5. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
Sharma A; Thelma BK
J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
[TBL] [Abstract][Full Text] [Related]
6.
Shirvani P; Fassihi A
J Biomol Struct Dyn; 2022 Aug; 40(13):5965-5982. PubMed ID: 33475043
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic Receptor Tyrosine Kinases Directly Phosphorylate Focal Adhesion Kinase (FAK) as a Resistance Mechanism to FAK-Kinase Inhibitors.
Marlowe TA; Lenzo FL; Figel SA; Grapes AT; Cance WG
Mol Cancer Ther; 2016 Dec; 15(12):3028-3039. PubMed ID: 27638858
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and biological evaluation of novel FAK scaffold inhibitors targeting the FAK-VEGFR3 protein-protein interaction.
Gogate PN; Ethirajan M; Kurenova EV; Magis AT; Pandey RK; Cance WG
Eur J Med Chem; 2014 Jun; 80():154-166. PubMed ID: 24780592
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel focal adhesion kinase inhibitors using a hybrid protocol of virtual screening approach based on multicomplex-based pharmacophore and molecular docking.
Wu F; Xu T; He G; Ouyang L; Han B; Peng C; Song X; Xiang M
Int J Mol Sci; 2012 Nov; 13(12):15668-78. PubMed ID: 23443087
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, biological evaluation, and molecular dynamics (MD) simulation studies of three novel F-18 labeled and focal adhesion kinase (FAK) targeted 5-bromo pyrimidines as radiotracers for tumor.
Fang Y; Wang D; Xu X; Liu J; Wu A; Li X; Xue Q; Wang H; Wang H; Zhang H
Eur J Med Chem; 2017 Feb; 127():493-508. PubMed ID: 28109944
[TBL] [Abstract][Full Text] [Related]
11. Exploring the interaction between human focal adhesion kinase and inhibitors: a molecular dynamic simulation and free energy calculations.
Zhan JY; Zhang JL; Wang Y; Li Y; Zhang HX; Zheng QC
J Biomol Struct Dyn; 2016 Nov; 34(11):2351-66. PubMed ID: 26549408
[TBL] [Abstract][Full Text] [Related]
12. Molecular dynamics guided insight, binding free energy calculations and pharmacophore-based virtual screening for the identification of potential VEGFR2 inhibitors.
Rathi E; Kumar A; Kini SG
J Recept Signal Transduct Res; 2019; 39(5-6):415-433. PubMed ID: 31755336
[TBL] [Abstract][Full Text] [Related]
13. Allosteric regulation of focal adhesion kinase by PIP₂ and ATP.
Zhou J; Bronowska A; Le Coq J; Lietha D; Gräter F
Biophys J; 2015 Feb; 108(3):698-705. PubMed ID: 25650936
[TBL] [Abstract][Full Text] [Related]
14. Progress in the Development of Small Molecular Inhibitors of Focal Adhesion Kinase (FAK).
Lu Y; Sun H
J Med Chem; 2020 Dec; 63(23):14382-14403. PubMed ID: 33058670
[TBL] [Abstract][Full Text] [Related]
15. Structure-based discovery of cellular-active allosteric inhibitors of FAK.
Tomita N; Hayashi Y; Suzuki S; Oomori Y; Aramaki Y; Matsushita Y; Iwatani M; Iwata H; Okabe A; Awazu Y; Isono O; Skene RJ; Hosfield DJ; Miki H; Kawamoto T; Hori A; Baba A
Bioorg Med Chem Lett; 2013 Mar; 23(6):1779-85. PubMed ID: 23414845
[TBL] [Abstract][Full Text] [Related]
16. Discovery and characterization of novel allosteric FAK inhibitors.
Iwatani M; Iwata H; Okabe A; Skene RJ; Tomita N; Hayashi Y; Aramaki Y; Hosfield DJ; Hori A; Baba A; Miki H
Eur J Med Chem; 2013 Mar; 61():49-60. PubMed ID: 22819505
[TBL] [Abstract][Full Text] [Related]
17. Identification of potential PKC inhibitors through pharmacophore designing, 3D-QSAR and molecular dynamics simulations targeting Alzheimer's disease.
Iqbal S; Anantha Krishnan D; Gunasekaran K
J Biomol Struct Dyn; 2018 Nov; 36(15):4029-4044. PubMed ID: 29182053
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel discoidin domain receptor 1 (DDR1) inhibitors using E-pharmacophore modeling, structure-based virtual screening, molecular dynamics simulation and MM-GBSA approaches.
Nada H; Lee K; Gotina L; Pae AN; Elkamhawy A
Comput Biol Med; 2022 Mar; 142():105217. PubMed ID: 35032738
[TBL] [Abstract][Full Text] [Related]
19. Pharmacophore modeling, multiple docking, and molecular dynamics studies on Wee1 kinase inhibitors.
Hu Y; Zhou L; Zhu X; Dai D; Bao Y; Qiu Y
J Biomol Struct Dyn; 2019 Jul; 37(10):2703-2715. PubMed ID: 30052133
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel FAK and S6K1 dual inhibitors from natural compounds via ADMET screening and molecular docking.
Thiyagarajan V; Lin SH; Chang YC; Weng CF
Biomed Pharmacother; 2016 May; 80():52-62. PubMed ID: 27133039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
